1-4 of 4
David L. Bajor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial

Tithi Biswas, Afshin Dowlati, Charles A. Kunos, John J. Pink, Nancy L. Oleinick, Shakun Malik, Pingfu Fu, Shufen Cao, Debora S. Bruno, David L. Bajor, Monaliben Patel, Stanton L. Gerson, Mitchell Machtay
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 646–652.
https://doi.org/10.1158/1078-0432.CCR-21-2025
Published: 15 February 2022
View article titled, Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Open the PDF for Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Christos Fountzilas, David L. Bajor, Sarbajit Mukherjee, Joel Saltzman, Agnieszka K. Witkiewicz, Orla Maguire, Hans Minderman, Ram Nambiar, Hanna R. Rosenheck, Erik S. Knudsen, Jason B. Muhitch, Scott I. Abrams, Chong Wang, Alan D. Hutson, Kristopher Attwood, Karen A. Hicks, Jennifer A. Jurcevic, Pawel Kalinski, Renuka Iyer, Patrick M. Boland
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6726–6736.
https://doi.org/10.1158/1078-0432.CCR-21-1650
Published: 15 December 2021
View article titled, Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Open the PDF for Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O'Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana P. Ferreira, Byung S. Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-21-1047
Published: 15 August 2021
View article titled, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Open the PDF for Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety

David L. Bajor, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1192–1194.
https://doi.org/10.1158/1078-0432.CCR-11-3322
Published: 01 March 2012
View article titled, Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety
Open the PDF for Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety in another window
Includes: Supplementary data